Evidence map›Paper›PMID 30733413›Full record

ArticleScience (New York, N.Y.)2019

An ingestible self-orienting system for oral delivery of macromolecules.

Alex Abramson, Ester Caffarel-Salvador, Minsoo Khang, David Dellal, David Silverstein, Yuan Gao, Morten Revsgaard Frederiksen, Andreas Vegge, František Hubálek, Jorrit J Water and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 1 pooled it
47.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 1 synthesis or guideline pooled it, 416 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Tableting of nanoparticle-based formulations for oral delivery: Enhancing biopharmaceutical performance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Physical Intelligence in Small-Scale Robots and Machines.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 4 countries.

Alex AbramsonDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-4876-9751
Ester Caffarel-SalvadorDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-2844-7598
Minsoo KhangDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-1731-6258
David DellalInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-9558-3517
David SilversteinDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-8725-7444
Yuan GaoDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-1762-0121
Morten Revsgaard FrederiksenGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0003-0000-4426
Andreas VeggeGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.
František HubálekGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0003-3983-7900
Jorrit J WaterGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0001-5267-0637
Anders V FriderichsenGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0002-0485-4906
Johannes FelsGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0002-6616-6746
Rikke Kaae KirkGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.
Cody ClevelandDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-2973-8530
Joy CollinsDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9232-4517
Siddartha TamangDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Alison HaywardDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9581-8563
Tomas LandhGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.
Stephen T BuckleyGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0001-9804-7242
Niclas RoxhedDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-7147-6730
Ulrik RahbekGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Copenhagen, Denmark.ORCID 0000-0002-1255-0232
Robert LangerDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. rlanger@mit.edu ctraverso@bwh.harvard.edu.ORCID 0000-0003-4255-0492
Giovanni TraversoDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. rlanger@mit.edu ctraverso@bwh.harvard.edu.ORCID 0000-0001-7851-4077
Massachusetts Institute of Technology · USNovo Nordisk (Denmark) · DKBrigham and Women's Hospital · US

Funding

CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244
6 · The paper itself

Abstract

Biomacromolecules have transformed our capacity to effectively treat diseases; however, their rapid degradation and poor absorption in the gastrointestinal (GI) tract generally limit their administration to parenteral routes. An oral biologic delivery system must aid in both localization and permeation to achieve systemic drug uptake. Inspired by the leopard tortoise's ability to passively reorient, we developed an ingestible self-orienting millimeter-scale applicator (SOMA) that autonomously positions itself to engage with GI tissue. It then deploys milliposts fabricated from active pharmaceutical ingredients directly through the gastric mucosa while avoiding perforation. We conducted in vivo studies in rats and swine that support the applicator's safety and, using insulin as a model drug, demonstrated that the SOMA delivers active pharmaceutical ingredient plasma levels comparable to those achieved with subcutaneous millipost administration.

Indexed as

Administration, OralAnimalsDrug Delivery SystemsInsulinIntestinal AbsorptionMacromolecular SubstancesPolyestersRatsStainless SteelSwineInsulinMacromolecular SubstancespolycaprolactonePolyestersStainless Steel

Identifiers

PMID30733413
PMCPMC6430586
OpenAlexW2913582983

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.